This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > LY-900014 (ultra-rapid lispro) for adults with type 1 diabetes mellitus

< Back

LY-900014 (ultra-rapid lispro) for adults with type 1 diabetes mellitus


Endocrine, Nutritional and Metabolic

February 2019

LY-900014 (ultra-rapid lispro) is in development for the treatment of adult patients with type 1 diabetes mellitus. Type 1 diabetes mellitus is a condition which usually starts early in life and occurs as a result of the pancreas not producing enough (or sometimes any) insulin. This results in elevated blood sugar levels which can damage many organs in the body. Type 1 diabetes usually runs in families. While type 1 diabetes cannot be cured, having regular, at least daily, injections of insulin can keep blood sugar levels stable. However some people, despite having regular injections of insulin, still do not have stable blood sugar levels.
LY-900014 is a new formulation of insulin lispro that contains certain ingredients designed to increase the speed of insulin lispro absorption. Insulin lispro acts by copying the way naturally produced insulin works in people without diabetes. LY-900014 is administered by insulin pump and early studies have demonstrated rapid absorption of insulin lispro and improved glucose control after meals. If licensed, LY-900014 will offer a new option in insulin therapy for type 1 diabetes with the potential to help to keep blood sugar in range after eating.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts